By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
Metrion combines robust high-throughput KV7 assay capability with deep expertise in voltage gated potassium ion channels to help biotech and pharma teams advance programmes in pain and epilepsy with confidence.
Metrion delivers scalable KV7 IV profiling with the data quality and scientific support needed to advance ion channel programmes efficiently.
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.